Previous Summit

align="left">In 2010, much emphasis has been placed on helping Europe climb back to the top of the R&D ladder. The European pharmaceutical sector must currently focus on innovative solutions which can integrate seamlessly with existing technologies and strategies, which are key factors in bringing drugs to market quicker and more effectively. Given the multitude of new pharmaceuctical R&D institutes and the determination of the EU to revive Europe's status as an innovation leader in drug discovery, returns on such R&D investment over the next few years could potentially boom. Leaders in the R&D space know that now is the time to commit to drug discovery.

"This meeting provided an excellent opportunity to meet key thinkers in the clinical study Pharma space and to present the contributions of our technology to them."

Scott Watson, Aperio

Who was there...

Partners

Delegates

David Heard

David Heard
Head of Preclinical Safety Informatics
Novartis

www.novartis.com

Ted Torphy

Ted Torphy
VP and Lead for External Innovation
Johnson & Johnson

www.jnj.com

Martin Klumpp

Martin Klumpp
Lab Head, Assay Development and Screening
Novartis

www.novartis.com

Massimo De Francesco

Massimo De Francesco
Global Head of Drug Discovery Informatics
Merck Serono

www.merckserono.com

Olivier Grenet

Olivier Grenet
Group Head Genome Biology
Novartis

www.novartis.com

Joachim Scholpp

Joachim Scholpp
Director of Exploritory Clinical Science
Nycomed

www.nycomed.com

Gunther Busam

Gunther Busam
Head of Global Sourcing Technology & R&D
Novartis

www.novartis.com

Edgar Jacoby

Edgar Jacoby
Head of Molecular and Library Informatics
Novartis

www.novartis.com

View all